AccessibilityHelp
Johnson & Johnson logo

Johnson & Johnson(NYSE) JNJ

Market Cap$644.91BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1968)+146,949%
5 Year+88%
1 Year+42%
1 Month-1%
Premium Feature
Moneyball Superscore
80/100
$262.78
-1.81%
-4.83Today
Johnson & Johnson last closing stock price
MetricPriceDate
Last closeUSD 267.612026-10-22
Johnson & Johnson stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.66%USD 253.282026-10-15
1 month-0.59%USD 269.192026-09-22
3 month+2.1%USD 262.112026-07-24
Year to date+31.39%USD 203.672025-12-31
1 year+41.83%USD 188.692025-10-22
3 year+92.5%USD 139.022023-10-23
5 year+87.95%USD 142.382021-10-22
Since inception+146,948.76%USD 0.181968-01-02

Johnson & Johnson Financials at a Glance

Market Cap

$644.91BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$99.34B

Net Income (TTM)

$16.10B

EPS (TTM)

$6.59

P/E Ratio

40.59

Dividend

$5.28

Beta (Volatility)

0.16 (Low)

Price

$262.78

Volume

1,563,694.903

Open

$265.82

Previous Close

$267.61

Daily Range

$262.40 - $266.03

52-Week Range

$184.66 - $281.07

Estimated Earnings Date

Jan 20, 2027

JNJ News

Amgen and Johnson & Johnson logos source-TMF

2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)

Prosper Junior BakinyOct 20, 2026
what-does-johnson-and-johnson-own-infographic

What Companies Does Johnson & Johnson Own?

Matt DiLalloOct 18, 2026
Person standing in pharmacy aisle holding mouthwash and searching on phone

How to Buy Kenvue Stock (KVUE) in 2026

Lyle DalyOct 18, 2026
JNJ. imagesource TMF.jpg

Should You Invest in This Dividend King on the Dip?

Prosper Junior BakinyOct 17, 2026
growth women investing stocks-1200x800-5b2df79

When the Stock Market Gets Dangerous, These 6 Investments Have a History of Holding Up

Matt DiLalloOct 17, 2026
financial analysis company filing business papers

Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.

James BrumleyOct 17, 2026
GettyImages-1332377628-1281x854-f43835d.jpg

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Jack DelaneyOct 16, 2026
featured-transcript-logo-template.jpg

Johnson & Johnson: 3 Key Takeaways for Long-Term Investors

The Motley Fool TeamOct 16, 2026
Page 1

JNJ: Motley Fool Moneyball Superscore

80

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Johnson & Johnson

Johnson & Johnson NYSE:JNJ makes medicine and medical tools. These products treat cancer and help doctors perform surgery. The company also makes contact lenses and bone implants.

What the Company Makes

  • Innovative Medicine: Prescription drugs for complex diseases; segment sales were $48.6 billion for the fiscal nine months of 2026.
  • MedTech: Surgical instruments and medical devices; segment sales were $26.2 billion for the fiscal nine months of 2026.
  • Oncology: Treatments for cancer like Darzalex; sales were $22.0 billion for the fiscal nine months of 2026.
  • Immunology: Drugs for inflammatory bowel disease; sales were $11.4 billion for the fiscal nine months of 2026.
  • Orthopaedics: Implants for hip and knee repairs; sales were $7.1 billion for the fiscal nine months of 2026.

Expansion and Strategy

  • Acquired Intra-Cellular Therapies on April 2, 2025, to add the mental health drug Caplyta to its portfolio.
  • Bought Firefly Bio, Inc. in 2026 to expand research into next-generation biotechnology solutions.
  • Plans to complete the separation of its Orthopaedics business by mid-2027 to simplify its healthcare structure.
  • Launched Inlexzo in the U.S. to broaden its offerings for oncology patients.

How It Stands Out

The company operates a global healthcare network focused on research-intensive drugs and specialized medical instruments. It balances long-term pharmaceutical discovery with steady demand for surgical tools and vision products. Operational strength is supported by a large research budget and distribution to hospitals around the world.

Checking the Books

  • Worldwide sales were $74.8 billion for the fiscal nine months of 2026, up 7.4% year over year.
  • Market capitalization reached $665.6 billion in Q3 fiscal year 2026, up 50.9% year over year.
  • Sales of the drug Stelara declined 56.4% in the fiscal nine months of 2026 due to biosimilar competition.
  • The company recorded a $5.5 billion charge in the fiscal third quarter of 2026 for legal settlements.

Evolution of a Giant

Johnson & Johnson is shifting its focus toward high-growth medicine and medical technology while moving away from slower segments. This strategy helps the company manage patent expirations and legal issues while funding new healthcare innovations.

AI Generated • Oct 22, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

140,800

CEO

Joaquin Duato, MBA

Website

www.jnj.com

Headquarters

New Brunswick, NJ 08933, US

JNJ Financials

Key Financial Metrics (TTM)

Gross Margin

68.81%

Operating Margin

25.70%

Net Income Margin

16.20%

Return on Equity

19.55%

Return on Capital

19.77%

Return on Assets

8.15%

Earnings Yield

2.46%

Dividend Yield

1.97%

Payout Ratio

79.01%

Stock Overview

Market Cap

$644.91BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.41B

Volume

1.56M

Avg. Volume

7.05M

Financials (TTM)

Gross Profit

$68.35B

Operating Income

$25.53B

EBITDA

$30.81B

Operating Cash Flow

$26.16B

Capital Expenditure

-$5.57B

Free Cash Flow

$20.59B

Cash & ST Invst.

$17.23B

Total Debt

$44.65B

Johnson & Johnson Performance Analysis

Johnson & Johnson annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 80,062,000,000-14.6%
20232023-12-31USD 85,152,000,0006.4%
20242024-12-31USD 88,819,000,0004.3%
20252025-12-31USD 94,178,000,0006.0%
Johnson & Johnson sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-12-282.4%
Q12026-03-29-2.0%
Q22026-06-285.2%
Q32026-09-270.4%
Johnson & Johnson annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 6.73-13.7%
20232023-12-31USD 5.53-17.8%
20242024-12-31USD 5.794.6%
20252025-12-31USD 11.0390.6%
Johnson & Johnson sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-12-28-0.9%
Q12026-03-291.9%
Q22026-06-286.1%
Q32026-09-27-96.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$25.40B

+5.9%

Gross Profit

$18.54B

+11.1%

Gross Margin

73.00%

N/A

Market Cap

$644.91BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.55M

N/A

Employees

141,700

N/A

Net Income

$210.00M

-95.9%

EBITDA

$6.37B

-31.5%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$17.23B

-7.2%

Total Debt

$44.65B

-2.5%

Accounts Receivable

$18.99B

+7.8%

Inventory

$15.38B

+8.7%

Long Term Debt

$35.80B

-9.2%

Short Term Debt

$8.85B

+38.6%

Return on Assets

8.15%

N/A

Return on Invested Capital

17.98%

N/A

Free Cash Flow

$6.36B

-24.1%

Operating Cash Flow

$7.72B

-15.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ABBVAbbVie Inc.
$284.90-0.10%
MRKMerck & Co., Inc.
$144.87-1.61%
NVSNovartis AG
$150.81-3.49%
AZNAstraZeneca PLC
$171.30-0.74%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.83+2.13%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$86.24+5.03%
NOKNokia
$8.16+3.55%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$50.75-5.05%

Questions About JNJ

What is the current price of Johnson & Johnson?

Johnson & Johnson is trading at $262.98 per share.

What is the 52-week range for Johnson & Johnson?

Over the past 52 weeks, Johnson & Johnson has traded between $184.66 and $281.07.

How much debt does Johnson & Johnson have?

As of the most recent reporting period, Johnson & Johnson reported total debt of $44.65B.

How much cash does Johnson & Johnson have on hand?

Johnson & Johnson reported $16.91B in cash and cash equivalents in its most recent financial results.

What is Johnson & Johnson’s dividend yield?

Johnson & Johnson currently has a dividend yield of 1.97%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services